Despite Headwinds US IPOs Show Few Signs Of Slowing In Q3

Fifteen drug development firms raised $1.4bn via initial public offerings in the US during the third quarter, which is equal to the quarterly average during the first half of the year and shows that despite recent biotechnology stock headwinds IPOs have not slowed – at least, not yet.

The July-to-September IPO total is on par with the 29 offerings that raised $2.8bn during the first half of 2015 (an average of 15 offerings totaling $1.4bn per quarter)